Company: PTHS
Filing Date: 2025-09-16
Form Type: 8-K/A
Source: 0001753926-25-001500
Chunk: 35

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-09-16
Form: 8-K/A
Chunk 35
---
 and pediatric patients one year of age and older in January 2024.

Channel has had net losses since inception, and Channel has had an accumulated deficit of approximately $26.9 million and $17.9 million as of June 30, 2025 and June 30, 2024, respectively, which includes a net loss of approximately $3.4 million for the three months ended June 30, 2025, and approximately $1.8 million for the three months ended June 30, 2024, respectively, and includes a net loss of approximately $5.4 million for the six months ended June 30, 2025, and approximately $4.3 million the six months ended June 30, 2024, respectively.

LNHC has also had net losses since inception, and LNHC has had a total parent company net investment balance of approximately $(9.0) million and $10.6 million as of June 30, 2025 and June 30, 2024, respectively, which includes a net loss of approximately $17.0 million for the three months ended June 30, 2025, and approximately $5.7 million for the three months ended June 30, 2024, respectively, and includes a net loss of approximately $24.5 million for the six months ended June 30, 2025, and approximately $13.2 million the six months ended June 30, 2024, respectively.

Overall, these conditions have raised substantial doubt regarding our ability to continue as a going concern beyond one year of the filing of our consolidated financial statements. Our ability to continue as a going concern is dependent upon the ability to complete clinical studies and implement our business plan, raise capital, generate sufficient revenues and to control operating expenses.

We expect to continue to incur significant expenses and operating losses until revenue from ZELSUVMI is sufficient to fund our operations, if ever. Our net losses may fluctuate significantly from quarter to quarter and year to year. Our expenses may increase substantially, as we:

| ● | commercialize 
 ZELSUVMI;     |

| ● | operate our manufacturing facility, at which we create the API for ZELSUVMI; |

| ● | work                                                                              
 with third-party contract manufacturers to produce the ZELSUVMI finished product; |

| ● | maintain                                                                                                                    
 or expand a sales, commercial and distribution infrastructure and manufacturing and logistics capabilities to commercialize 
 currently approved products as well as any future products